When lean and tumor-prone FVB mice were challenged with a supra-therapeutic dose by combination of continuous infusion and daily injection, FGF19v induced only a two-fold increase in hepatic BrdU incorporation compared with vehicle-treated mice, whereas FGF19 induced on average >9 fold increase. This evidence concerns the gene FGF19 and neoplasm.